Aptinyx loses half of value on latest painful DPN failure

8 April 2022

US CNS specialist Aptinyx (Nasdaq: APTX) lost nearly half of its market value on Thursday after announcing a second Phase II failure of NYX-2925 in painful diabetic peripheral neuropathy (DPN).

In the latest failure – following the first in 2019 – NYX-2925 did not achieve statistically-significant separation from placebo on the Phase IIb study’s primary endpoint of change from baseline in average daily pain on the numeric rating scale during week 12.

No way forward in painful DPN

This article is accessible to registered users, to continue reading please register for free. A free trial will give you access to exclusive features, interviews, round-ups and commentary from the sharpest minds in the pharmaceutical and biotechnology space for a week. If you are already a registered user please login. If your trial has come to an end, you can subscribe here.

Try before you buy

Free

7 day trial access

Take a Free Trial

All the news that moves the needle in pharma and biotech
Exclusive features, podcasts, interviews, data analyses and commentary from our global network of life sciences reporters.
Receive The Pharma Letter daily news bulletin, free forever.

Become a subscriber

£820

Or £77 per month

Subscribe Now

Unfettered access to industry-leading news, commentary and analysis in pharma and biotech.
Updates from clinical trials, conferences, M&A, licensing, financing, regulation, patents & legal, executive appointments, commercial strategy and financial results.
Daily roundup of key events in pharma and biotech.
Monthly in-depth briefings on Boardroom appointments and M&A news.
Choose from a cost-effective annual package or a flexible monthly subscription

The Pharma Letter is an extremely useful and valuable Life Sciences service that brings together a daily update on performance people and products. It’s part of the key information for keeping me informed

Chairman, Sanofi Aventis UK